Surgery versus endoscopy with digital single-operator cholangioscopy-guided therapy for Mirizzi syndrome: The SEIZE study

BACKGROUND AND STUDY AIMS: The management of Mirizzi syndrome has been primarily surgical, but there are no comparisons between surgical and digital single-operator cholangioscopy (dSOC)-guided treatment. The objective is to compare the safety and outcomes of both approaches. PATIENTS AND METHODS: A large multicentre international retrospective analysis was conducted comparing dSOC and surgery in patients with type II-IV Mirizzi syndrome between January 2005 and June 2023. Patients with postsurgical anatomy, Mirizzi type I or V, or previous cholecystectomy were excluded. RESULTS: In total, 290 patients were included (dSOC n=176, surgery n=114). At baseline, patients undergoing dSOC were older (p=0.006) and exhibited more comorbidities. While technical success was lower with dSOC (89.8% vs. 96.5%, p=0.035), the need for reintervention was comparable after a median follow-up duration of 741.5 days (IQR 320-1781) vs. 346 (IQR 67-1220) days (p=0.009). Overall adverse events (AE) (10.2% vs. 41.2%, p<0.001) and severe AE (1.7% vs. 15.8%, p<0.001) occurred less frequently with dSOC, findings that were confirmed with propensity score-matching. A lower need for hepaticojejunostomy (8.2% vs. 25.4%, p=0.006) and, lower rates of conversion to open surgery (6.0% vs. 22.8%, p=0.009) were observed in patients undergoing elective cholecystectomy following dSOC when compared to the primary surgery group. CONCLUSIONS: Our study demonstrates that the use of dSOC for Mirizzi syndrome is effective, showing superior safety despite being used to treat patients with more underlying comorbidity. dSOC seems valuable in downgrading the extent of subsequent surgery, by potentially reducing the need for hepaticojejunostomy and conversion to open surgery.

Publication History

Received: 02 September 2024

Accepted after revision: 28 May 2025

Accepted Manuscript online:
28 May 2025